PMID- 34225420
OWN - NLM
STAT- MEDLINE
DCOM- 20210707
LR  - 20210707
IS  - 0376-2491 (Print)
IS  - 0376-2491 (Linking)
VI  - 101
IP  - 25
DP  - 2021 Jul 6
TI  - [Cohort study of efficacy and safety of polatuzumab vedotin combined with 
      immunochemotherapy in patients with relapse/refractory diffuse large B cell 
      lymphoma].
PG  - 1985-1990
LID - 10.3760/cma.j.cn112137-20201030-02971 [doi]
AB  - Objective: To investigate the efficacy and tolerability of Polatuzumab 
      vedotin+rituximab+/-bendamustine (Pola-(B)R) in relapse/refractory diffuse large B 
      cell lymphoma (R/R DLBCL) patients. Methods: The clinical data of 21 patients 
      enrolled in Chinese Pola compassionate use program (CUP) in 4 centers from 
      November 2019 to August 2020 were collected. There were 15 males and 6 females, 
      and the median age was 56 years (ranged 25-76 years). Of the patients, 10 cases 
      received Pola-BR regimen and the other 11 received Pola-R. Their clinical 
      features, regimens, efficacy, and adverse events (AEs) were retrospectively 
      analyzed. Results: Twenty-one patients with at least one efficacy evaluation were 
      included. At data analysis cut-off point (12 Aug. 2020), the best overall 
      response (BOR) rate was 81.0% (17/21) and the complete response (CR) rate was 
      19.0% (4/21). Kaplan-Meier survival estimation was performed, at a median 
      follow-up of 54 days, three patients (14.3%) had disease progressed, and 18 
      patients (85.7%) were censored; the median progression-free survival (mPFS) was 
      estimated to be 148 days. The incidence of adverse effects (AEs) of any grade was 
      higher in Pola-BR group than Pola-R group (80.0% vs 63.6%). However, the 
      incidence of grade 3-4 AEs were close in the two groups (30.0% vs 29.3%). The 
      most common hematological toxicities were thrombocytopenia (28.6%, 6/21), 
      neutropenia (28.6%, 6/21) and anemia (14.3%, 3/21), respectively. One patient 
      with pneumonia and 1 patient with hemophagocytic syndrome recovered after 
      symptomatic treatment. No peripheral neuropathy of grade>/=2 was observed. 
      Conclusions: The preliminary data suggested that, for heavily treated Chinese R/R 
      DLBCL, the Pola-(B)R regimen still achieves promising efficacy and tolerable 
      safety.
FAU - Wu, J Q
AU  - Wu JQ
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing 210009, China.
FAU - Liu, Y Y
AU  - Liu YY
AD  - Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou 450008, China.
FAU - Li, F
AU  - Li F
AD  - Department of Hematology, the First Affiliated Hospital of Nanchang University, 
      Nanchang 330006, China.
FAU - Wu, X Z J
AU  - Wu XZJ
AD  - Department of Hematology/Lymphoma Center, the First Affiliated Hospital of Hainan 
      Medical University, Haikou 570102, China.
FAU - Yao, Z H
AU  - Yao ZH
AD  - Department of Internal Medicine, Henan Cancer Hospital, Affiliated Cancer 
      Hospital of Zhengzhou University, Zhengzhou 450008, China.
FAU - Kong, F C
AU  - Kong FC
AD  - Department of Hematology, the First Affiliated Hospital of Nanchang University, 
      Nanchang 330006, China.
FAU - Zhou, W L
AU  - Zhou WL
AD  - Department of Hematology/Lymphoma Center, the First Affiliated Hospital of Hainan 
      Medical University, Haikou 570102, China.
FAU - Tang, W Y
AU  - Tang WY
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing 210009, China.
FAU - Teng, Y
AU  - Teng Y
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing 210009, China.
FAU - Feng, J F
AU  - Feng JF
AD  - Department of Medical Oncology, Jiangsu Cancer Hospital, Jiangsu Institute of 
      Cancer Research/the Affiliated Cancer Hospital of Nanjing Medical University, 
      Nanjing 210009, China.
LA  - chi
GR  - H2019100/Research Project of Jiangsu Commission of Health/
GR  - Y-2019Roche-075/Xisike-Roche Oncology Research Fund/
PT  - Journal Article
PL  - China
TA  - Zhonghua Yi Xue Za Zhi
JT  - Zhonghua yi xue za zhi
JID - 7511141
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Immunoconjugates)
RN  - 4F4X42SYQ6 (Rituximab)
RN  - KG6VO684Z6 (polatuzumab vedotin)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antibodies, Monoclonal
MH  - *Antineoplastic Combined Chemotherapy Protocols/therapeutic use
MH  - Cohort Studies
MH  - Female
MH  - Humans
MH  - Immunoconjugates
MH  - *Lymphoma, Large B-Cell, Diffuse/drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Retrospective Studies
MH  - Rituximab/therapeutic use
MH  - Treatment Outcome
EDAT- 2021/07/06 06:00
MHDA- 2021/07/08 06:00
CRDT- 2021/07/05 22:36
PHST- 2021/07/05 22:36 [entrez]
PHST- 2021/07/06 06:00 [pubmed]
PHST- 2021/07/08 06:00 [medline]
AID - 10.3760/cma.j.cn112137-20201030-02971 [doi]
PST - ppublish
SO  - Zhonghua Yi Xue Za Zhi. 2021 Jul 6;101(25):1985-1990. doi: 
      10.3760/cma.j.cn112137-20201030-02971.